Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lantheus Holdings, Inc. (LNTH)
USD104.03
-1.36 (-1.29%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
331 Treble Cove Road 1862
Bedford, MA, US
Bedford, MA, US
CEO
Mary Anne Heino
Website
lantheus.com
IPO
2015-06-25
CIK 1521036 ISIN US5165441032
Description
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Progenics | PGNX | 2019-11-12 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD104.03
-1.36 (-1.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
959.3K
Beta
-0.04
Float Shares
58.10M
Free Float %
89.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.30% | +6.92% | +19.41% | +40.03% | +76.57% | +44.60% | +21.01% | -3.43% | +385.76% | +4,215.25% | +1,321.42% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (17 ratings, all time)
Buy
Price Targets & DCF
Current price
104.03
Low
94.00
-9.6%
Consensus
103.50
-0.5%
Median
102.50
-1.5%
High
115.00
+10.5%
DCF (Unlevered)
729.72
+601.5%
DCF (Levered)
536.03
+415.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
85% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 9 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
95.67
-8.0%
|
| Last Quarter | 5 |
97.20
-6.6%
|
| Last Year | 10 |
86.00
-17.3%
|
| All Time | 16 |
106.13
+2.0%
|
Quality scores
Altman Z-Score
5.16
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.5% Q1'26: +1.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-21.8% Q1'26: +76.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.5% Q1'26: +32.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+21.6% ★ Q1'26: +21.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+33.9% ★ Q1'26: +34.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-4.5% ★ Q1'26: -8.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 9 EPS Ana. |
Dec 2027 10 Rev. Ana. 8 EPS Ana. |
Dec 2028 9 Rev. Ana. 3 EPS Ana. |
Dec 2029 4 Rev. Ana. 1 EPS Ana. |
Dec 2030 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
293.46M
est: 293.70M (-0.1%)
|
301.85M
est: 298.28M (+1.2%)
|
331.38M
est: 327.17M (+1.3%)
|
343.37M
est: 340.90M (+0.7%)
|
347.34M
est: 348.73M (-0.4%)
|
339.41M
est: 337.51M (+0.6%)
|
425.21M
est: 407.40M (+4.4%)
|
935.06M
est: 916.62M (+2.0%)
|
1.30B
est: 1.44B (-9.8%)
|
1.53B
est: 1.52B (+0.9%)
|
1.54B
est: 1.50B (+2.6%)
|
1.46B
1.42B – 1.58B
-2.7% YoY
|
1.66B
1.55B – 1.84B
+13.3% YoY
|
1.87B
1.87B – 1.87B
+12.9% YoY
|
2.02B
1.94B – 2.23B
+8.2% YoY
|
2.19B
2.10B – 2.42B
+8.3% YoY
|
| EBITDA |
46.59M
est: 47.59M (-2.1%)
|
73.18M
est: 68.40M (+7.0%)
|
77.19M
est: 72.20M (+6.9%)
|
80.81M
est: 61.79M (+30.8%)
|
55.62M
est: 48.41M (+14.9%)
|
22.69M
est: 51.48M (-55.9%)
|
-25.00M
est: 127.73M (-119.6%)
|
81.83M
est: 97.95M (-16.5%)
|
491.01M
est: 806.67M (-39.1%)
|
515.27M
est: 852.70M (-39.6%)
|
403.64M
est: 842.47M (-52.1%)
|
819.79M
797.48M – 886.71M
-2.7% YoY
|
928.99M
867.80M – 1.03B
+13.3% YoY
|
1.05B
1.05B – 1.05B
+12.9% YoY
|
1.13B
1.09B – 1.25B
+8.2% YoY
|
1.23B
1.18B – 1.35B
+8.3% YoY
|
| EBIT |
26.94M
est: 29.27M (-8.0%)
|
54.91M
est: 52.07M (+5.5%)
|
58.05M
est: 46.81M (+24.0%)
|
66.95M
est: 49.08M (+36.4%)
|
42.24M
est: 45.22M (-6.6%)
|
-2.00M
est: -11.44M (+82.5%)
|
-67.29M
est: 50.79M (-232.5%)
|
33.90M
est: 65.41M (-48.2%)
|
430.96M
est: 785.36M (-45.1%)
|
450.65M
est: 830.17M (-45.7%)
|
333.54M
est: 820.21M (-59.3%)
|
798.13M
776.41M – 863.28M
-2.7% YoY
|
904.44M
844.87M – 1.01B
+13.3% YoY
|
1.02B
1.02B – 1.02B
+12.9% YoY
|
1.10B
1.06B – 1.22B
+8.2% YoY
|
1.20B
1.15B – 1.32B
+8.3% YoY
|
| Net Income |
-14.75M
est: 31.38M (-147.0%)
|
26.76M
est: 25.04M (+6.9%)
|
123.39M
est: 145.23M (-15.0%)
|
40.52M
est: 30.15M (+34.4%)
|
31.67M
est: 27.46M (+15.3%)
|
-13.47M
est: -30.15M (+55.3%)
|
-71.28M
est: 6.98M (-1,121.9%)
|
28.07M
est: 33.67M (-16.6%)
|
326.66M
est: 428.48M (-23.8%)
|
312.44M
est: 465.95M (-32.9%)
|
233.56M
est: 376.39M (-37.9%)
|
367.64M
340.06M – 395.22M
-2.3% YoY
|
438.66M
411.14M – 466.18M
+19.3% YoY
|
478.14M
389.53M – 720.62M
+9.0% YoY
|
534.66M
505.23M – 605.68M
+11.8% YoY
|
588.27M
555.88M – 666.40M
+10.0% YoY
|
| SGA |
78.63M
est: 90.32M (-12.9%)
|
75.37M
est: 70.16M (+7.4%)
|
92.16M
est: 85.21M (+8.2%)
|
93.33M
est: 71.73M (+30.1%)
|
103.13M
est: 87.28M (+18.2%)
|
110.17M
est: 212.26M (-48.1%)
|
218.82M
est: 308.90M (-29.2%)
|
233.83M
est: 188.00M (+24.4%)
|
267.19M
est: 433.54M (-38.4%)
|
371.63M
est: 458.28M (-18.9%)
|
453.81M
est: 452.78M (+0.2%)
|
440.59M
428.60M – 476.56M
-2.7% YoY
|
499.28M
466.39M – 556.08M
+13.3% YoY
|
563.77M
563.75M – 563.79M
+12.9% YoY
|
609.91M
584.08M – 672.22M
+8.2% YoY
|
660.66M
632.69M – 728.16M
+8.3% YoY
|
| EPS |
-0.60
est: 0.44 (-237.0%)
|
0.84
est: 0.66 (+27.7%)
|
3.31
est: 1.09 (+202.7%)
|
1.06
est: 0.85 (+24.7%)
|
0.81
est: 1.13 (-28.1%)
|
-0.25
est: 0.45 (-155.1%)
|
-1.06
est: 0.41 (-356.5%)
|
0.41
est: 3.84 (-89.3%)
|
4.79
est: 6.23 (-23.1%)
|
4.52
est: 6.75 (-33.1%)
|
3.46
est: 5.57 (-37.9%)
|
5.28
4.97 – 5.77
-5.2% YoY
|
6.34
6.01 – 6.81
+20.1% YoY
|
7.71
5.69 – 10.53
+21.6% YoY
|
7.81
7.38 – 8.85
+1.3% YoY
|
8.60
8.12 – 9.74
+10.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-15 | Truist Securities | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
373.31M
OE per share TTM
5.56
Owner's Yield
6.34%
Maintenance CapEx ratio
2.07%
Maint CapEx / Avg PPE
17.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
112
Total invested
368.17M
Insider transactions (90d)
1
Beneficial owners (>5%)
43
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lantheus Alpha Therapy, LLC | 56.34M | 10.74% | — | 56.34M | — | 56.34M | CO | — | 2024-02-01 | ↗ |
| 2 | Lantheus Holdings, Inc. | 56.34M | 10.74% | — | 56.34M | — | 56.34M | CO | — | 2024-02-01 | ↗ |
| 3 | (1) BlackRock, Inc. | 10.68M | 15.80% | 10.58M | — | 10.68M | — | HC | Delaware | 2022-01-25 | ↗ |
| 4 | Armistice Capital, LLC | 5.20M | 7.80% | — | 5.20M | — | 5.20M | IA, OO | Delaware | 2021-02-16 | ↗ |
| 5 | Andrew J. M. Spokes | 5.06M | 7.30% | — | 5.06M | — | — | IN | United Kingdom | 2024-11-14 | ↗ |
| 6 | Daniel S. Short | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 7 | David T. Kim | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 8 | Edric C. Saito | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 9 | Hannah E. Dunn | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 10 | John R. Warren | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 11 | Joshua J. Dapice | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 12 | Mark C. Wehrly | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 13 | Michael G. Linn | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 14 | Nicolas Giauque | 5.06M | 7.30% | — | 5.06M | — | — | IN | France | 2024-11-14 | ↗ |
| 15 | Philip D. Dreyfuss | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 16 | Rajiv A. Patel | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 17 | Richard B. Fried | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 18 | Thomas G. Roberts, Jr. | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 19 | Varun N. Gehani | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 20 | William Seybold | 5.06M | 7.30% | — | 5.06M | — | — | IN | United States | 2024-11-14 | ↗ |
| 21 | Farallon Partners, L.L.C. | 4.93M | 7.10% | — | 4.93M | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 22 | Wellington Management Company LLP | 4.44M | 11.18% | — | 4.20M | — | — | IA | Massachusetts | 2020-04-09 | ↗ |
| 23 | The Vanguard Group - 23-1945930 | 4.32M | 6.38% | — | 65.4K | 4.20M | 117.5K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 24 | EIN #00-0000000 | 3.96M | 5.80% | — | 3.96M | — | 3.96M | IA, HC | Jersey, Channel Islands | 2024-02-14 | ↗ |
| 25 | Wellington Group Holdings LLP | 3.36M | 4.96% | — | 3.29M | — | — | HC | Massachusetts | 2021-12-10 | ↗ |
| 26 | Wellington Investment Advisors Holdings LLP | 3.36M | 4.96% | — | 3.29M | — | — | HC | Massachusetts | 2021-12-10 | ↗ |
| 27 | Wellington Management Group LLP | 3.36M | 4.96% | — | 3.29M | — | — | HC | Massachusetts | 2021-12-10 | ↗ |
| 28 | Farallon Healthcare Partners (GP), L.L.C. | 3.06M | 4.40% | — | 3.06M | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 29 | Farallon Healthcare Partners Master, L.P. | 3.06M | 4.40% | — | 3.06M | — | — | PN | Cayman Islands | 2024-11-14 | ↗ |
| 30 | 52-0556948 | 2.17M | 3.10% | 540.2K | — | 2.17M | — | IA | Maryland | 2022-02-14 | ↗ |
| 31 | Armistice Capital Master Fund Ltd. | 2.00M | 5.00% | — | 2.00M | — | 2.00M | CO | Delaware | 2020-05-26 | ↗ |
| 32 | Steven Boyd | 2.00M | 5.00% | — | 2.00M | — | 2.00M | HC, IN | Delaware | 2020-05-26 | ↗ |
| 33 | Wellington Trust Company, NA | 1.17M | 1.73% | — | 1.17M | — | — | BK | United States | 2022-02-04 | ↗ |
| 34 | Farallon Capital Offshore Investors II, L.P. | 830.0K | 1.20% | — | 830.0K | — | — | PN | Cayman Islands | 2024-11-14 | ↗ |
| 35 | Farallon Capital Institutional Partners, L.P. | 403.1K | 0.60% | — | 403.1K | — | — | PN | California | 2024-11-14 | ↗ |
| 36 | Farallon Capital Partners, L.P. | 367.4K | 0.50% | — | 367.4K | — | — | PN | California | 2024-11-14 | ↗ |
| 37 | Farallon Capital F5 Master I, L.P. | 135.7K | 0.20% | — | 135.7K | — | — | PN | Cayman Islands | 2024-11-14 | ↗ |
| 38 | Farallon F5 (GP), L.L.C. | 135.7K | 0.20% | — | 135.7K | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 39 | Farallon Capital Institutional Partners II, L.P. | 95.7K | 0.10% | — | 95.7K | — | — | PN | California | 2024-11-14 | ↗ |
| 40 | Farallon Institutional (GP) V, L.L.C. | 76.5K | 0.10% | — | 76.5K | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 41 | Four Crossings Institutional Partners V, L.P. | 76.5K | 0.10% | — | 76.5K | — | — | PN | Delaware | 2024-11-14 | ↗ |
| 42 | Farallon Capital (AM) Investors, L.P. | 54.2K | 0.10% | — | 54.2K | — | — | PN | Delaware | 2024-11-14 | ↗ |
| 43 | Farallon Capital Institutional Partners III, L.P. | 46.1K | 0.10% | — | 46.1K | — | — | PN | Delaware | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
112
-289 vs prev Q
New positions
20
Closed positions
301
Increased
59
Reduced
31
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 940.0K +940.0K (+100.0%) | 62.56B +62.6B (+100.0%) | 1.40% +1.398 pp | 0.09% +0.094 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 8.27M +669.0 (+0.0%) | 550.13M +126.2M (+29.8%) | 12.30% +0.232 pp | 0.01% +0.002 pp | USD109.37 -39.2% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 6.70M -253.0K (-3.6%) | 445.84M +89.3M (+25.0%) | 9.96% -0.182 pp | 0.01% +0.001 pp | USD39.87 +66.9% | 42 qtrs — |
| 4 | JANUS HENDERSON GROUP PLC | 5.71M -977.5K (-14.6%) | 379.82M +37.0M (+10.8%) | 8.49% -1.267 pp | 0.17% +0.014 pp | USD80.98 -17.8% | 17 qtrs — |
| 5 | FARALLON CAPITAL MANAGEMENT LLC | 5.43M +2.0M (+56.1%) | 361.20M +182.9M (+102.5%) | 8.07% +2.998 pp | 1.70% +0.974 pp | USD78.15 -14.8% | 12 qtrs — |
| 6 | FMR LLC | 4.32M +124.6K (+3.0%) | 287.73M +72.4M (+33.6%) | 6.43% +0.303 pp | 0.01% +0.004 pp | USD86.46 -23.0% | 30 qtrs — |
| 7 | STATE STREET CORP | 2.43M -69.8K (-2.8%) | 161.53M +33.5M (+26.1%) | 3.61% -0.034 pp | 0.01% +0.001 pp | USD25.10 +165.1% | 36 qtrs — |
| 8 | MORGAN STANLEY | 1.76M -2.1M (-54.7%) | 116.97M -81.9M (-41.2%) | 2.61% -3.046 pp | 0.01% -0.005 pp | USD55.16 +20.6% | 42 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.73M -28.0K (-1.6%) | 114.92M +24.9M (+27.7%) | 2.57% +0.007 pp | 0.01% +0.001 pp | USD36.54 +82.1% | 42 qtrs — |
| 10 | REINHART PARTNERS, INC. | 1.56M +214.8K (+15.9%) | 103.99M +34.9M (+50.4%) | 2.32% +0.357 pp | 3.11% +0.867 pp | USD61.50 +8.2% | 20 qtrs — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 1.42M +44.4K (+3.2%) | 94.20M +23.9M (+34.0%) | 2.11% +0.104 pp | 0.02% +0.005 pp | USD32.42 +105.3% | 36 qtrs — |
| 12 | SWEDBANK AB | 1.23M +— (+0.0%) | 81.77M +18.8M (+29.8%) | 1.83% +0.034 pp | 0.08% +0.015 pp | USD81.21 -18.1% | 10 qtrs — |
| 13 | NORGES BANK | 1.14M +1.1M (+100.0%) | 76.20M +76.2M (+100.0%) | 1.70% +1.703 pp | 0.01% +0.008 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 14 | CARMIGNAC GESTION | 1.12M +314.6K (+39.0%) | 74.67M +33.3M (+80.3%) | 1.67% +0.491 pp | 1.01% +0.393 pp | USD65.26 +2.0% | 7 qtrs — |
| 15 | POINT72 ASSET MANAGEMENT, L.P. | 1.01M +1.0M (+100.0%) | 67.51M +67.5M (+100.0%) | 1.51% +1.509 pp | 0.08% +0.076 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 16 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 828.0K +828.0K (+100.0%) | 55.10M +55.1M (+100.0%) | 1.23% +1.232 pp | 0.70% +0.704 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 17 | BANK OF AMERICA CORP /DE/ | 819.8K +302.0K (+58.3%) | 54.56M +28.0M (+105.4%) | 1.22% +0.464 pp | 0.00% +0.002 pp | USD60.68 +9.7% | 42 qtrs — |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | 817.2K +5.3K (+0.7%) | 54.39M +12.7M (+30.6%) | 1.22% +0.031 pp | 0.01% +0.001 pp | USD44.96 +48.0% | 43 qtrs — |
| 19 | NORTHERN TRUST CORP | 798.1K -46.1K (-5.5%) | 53.12M +9.8M (+22.7%) | 1.19% -0.045 pp | 0.01% +0.001 pp | USD30.61 +117.4% | 42 qtrs — |
| 20 | AMERICAN CENTURY COMPANIES INC | 769.0K +47.6K (+6.6%) | 51.18M +14.2M (+38.3%) | 1.14% +0.091 pp | 0.03% +0.007 pp | USD70.49 -5.6% | 22 qtrs — |
| 21 | JPMORGAN CHASE & CO | 738.5K -43.4K (-5.5%) | 49.15M +9.0M (+22.6%) | 1.10% -0.043 pp | 0.00% +0.001 pp | USD81.12 -18.0% | 39 qtrs — |
| 22 | TD ASSET MANAGEMENT INC | 711.9K -79.1K (-10.0%) | 47.38M +6.8M (+16.8%) | 1.06% -0.096 pp | 0.04% +0.005 pp | USD86.92 -23.4% | 43 qtrs — |
| 23 | MACKENZIE FINANCIAL CORP | 657.7K +156.1K (+31.1%) | 44.08M +18.4M (+71.3%) | 0.98% +0.246 pp | 0.05% +0.021 pp | USD87.21 -23.7% | 16 qtrs — |
| 24 | CITADEL ADVISORS LLC | 644.2K +124.8K (+24.0%) | 42.87M +16.2M (+60.9%) | 0.96% +0.200 pp | 0.01% +0.002 pp | USD67.61 -1.6% | 32 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 643.2K +13.4K (+2.1%) | 42.80M +10.5M (+32.5%) | 0.96% +0.038 pp | 0.01% +0.002 pp | USD43.17 +54.2% | 35 qtrs — |
| 26 | FREESTONE GROVE PARTNERS LP | 608.5K +594.1K (+4,114.8%) | 40.50M +39.8M (+5,368.7%) | 0.91% +0.884 pp | 0.29% +0.287 pp | USD66.19 +0.5% | 5 qtrs — |
| 27 | PRIVATE CAPITAL MANAGEMENT, LLC | 558.8K -1.8K (-0.3%) | 37.19M +8.4M (+29.3%) | 0.83% +0.013 pp | 3.41% +0.840 pp | USD37.63 +76.9% | 23 qtrs — |
| 28 | POLARIS CAPITAL MANAGEMENT, LLC | 538.0K -99.3K (-15.6%) | 35.80M +3.1M (+9.5%) | 0.80% -0.130 pp | 2.97% +0.822 pp | USD51.29 +29.8% | 2 qtrs — |
| 29 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 522.2K -52.5K (-9.1%) | 34.75M +5.3M (+17.9%) | 0.78% -0.062 pp | 0.10% +0.021 pp | USD46.95 +41.7% | 19 qtrs — |
| 30 | UBS ASSET MANAGEMENT AMERICAS INC | 499.9K +51.4K (+11.5%) | 33.27M +10.3M (+44.6%) | 0.74% +0.089 pp | 0.01% +0.002 pp | USD63.24 +5.2% | 32 qtrs — |
| 31 | PORTOLAN CAPITAL MANAGEMENT, LLC | 475.8K +178.6K (+60.1%) | 31.66M +16.4M (+107.7%) | 0.71% +0.274 pp | 1.70% +0.872 pp | USD73.13 -9.0% | 12 qtrs — |
| 32 | BANK OF NEW YORK MELLON CORP | 469.2K -18.6K (-3.8%) | 31.23M +6.2M (+24.8%) | 0.70% -0.014 pp | 0.01% +0.001 pp | USD26.63 +149.9% | 42 qtrs — |
| 33 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 416.3K -53.1K (-11.3%) | 27.71M +3.6M (+15.1%) | 0.62% -0.066 pp | 0.19% +0.031 pp | USD58.67 +13.4% | 19 qtrs — |
| 34 | EPOCH INVESTMENT PARTNERS, INC. | 407.5K -48.3K (-10.6%) | 27.12M +3.7M (+16.0%) | 0.61% -0.059 pp | 0.15% +0.026 pp | USD85.87 -22.5% | 4 qtrs — |
| 35 | SUMMIT STREET CAPITAL MANAGEMENT, LLC | 405.7K +405.7K (+100.0%) | 27.00M +27.0M (+100.0%) | 0.60% +0.603 pp | 4.24% +4.244 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 36 | AQR CAPITAL MANAGEMENT LLC | 403.6K +317.4K (+368.0%) | 26.86M +22.5M (+516.9%) | 0.60% +0.475 pp | 0.01% +0.011 pp | USD63.70 +4.5% | 17 qtrs — |
| 37 | UBS GROUP AG | 396.5K +75.3K (+23.5%) | 26.38M +9.9M (+60.2%) | 0.59% +0.121 pp | 0.00% +0.002 pp | USD81.15 -18.0% | 43 qtrs — |
| 38 | INVESCO LTD. | 366.1K -366.8K (-50.0%) | 24.37M -13.2M (-35.2%) | 0.54% -0.525 pp | 0.00% -0.002 pp | USD78.86 -15.6% | 38 qtrs — |
| 39 | VESTAL POINT CAPITAL, LP | 360.0K +190.0K (+111.8%) | 23.96M +15.2M (+174.8%) | 0.54% +0.287 pp | 0.81% +0.421 pp | USD63.59 +4.7% | 3 qtrs — |
| 40 | GOLDMAN SACHS GROUP INC | 357.1K -200.3K (-35.9%) | 23.77M -4.8M (-16.9%) | 0.53% -0.282 pp | 0.00% -0.001 pp | USD68.95 -3.5% | 40 qtrs — |
| 41 | BNP PARIBAS ARBITRAGE, SNC | 306.7K -352.6K (-53.5%) | 20.41M -13.4M (-39.6%) | 0.46% -0.506 pp | 0.01% -0.009 pp | USD83.18 -20.0% | 35 qtrs — |
| 42 | PACER ADVISORS, INC. | 255.3K -166.9K (-39.5%) | 16.99M -4.7M (-21.5%) | 0.38% -0.236 pp | 0.04% -0.011 pp | USD76.30 -12.8% | 13 qtrs — |
| 43 | DEUTSCHE BANK AG\ | 235.3K +37.7K (+19.1%) | 15.66M +5.5M (+54.5%) | 0.35% +0.062 pp | 0.01% +0.002 pp | USD65.50 +1.6% | 42 qtrs — |
| 44 | THOMPSON SIEGEL & WALMSLEY LLC | 234.5K -39.7K (-14.5%) | 15.61M +1.5M (+11.0%) | 0.35% -0.051 pp | 0.26% +0.035 pp | USD76.37 -12.9% | 6 qtrs — |
| 45 | MARSHALL WACE, LLP | 232.7K +197.9K (+569.2%) | 15.48M +13.7M (+768.2%) | 0.35% +0.295 pp | 0.01% +0.012 pp | USD70.93 -6.2% | 17 qtrs — |
| 46 | PRINCIPAL FINANCIAL GROUP INC | 227.1K +20.6K (+10.0%) | 15.11M +4.5M (+42.7%) | 0.34% +0.036 pp | 0.01% +0.002 pp | USD52.26 +27.3% | 35 qtrs — |
| 47 | AMERIPRISE FINANCIAL INC | 224.7K -25.2K (-10.1%) | 14.95M +2.1M (+16.7%) | 0.33% -0.031 pp | 0.00% +0.000 pp | USD72.98 -8.8% | 35 qtrs — |
| 48 | HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 224.5K +1.4K (+0.6%) | 14.94M +3.5M (+30.6%) | 0.33% +0.008 pp | 0.04% +0.009 pp | USD51.39 +29.5% | 2 qtrs — |
| 49 | FIL LTD | 214.8K +214.8K (+100.0%) | 14.30M +14.3M (+100.0%) | 0.32% +0.320 pp | 0.01% +0.011 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 50 | RHUMBLINE ADVISERS | 195.1K -19.0K (-8.9%) | 12.98M +2.0M (+18.2%) | 0.29% -0.022 pp | 0.01% +0.002 pp | USD28.29 +135.2% | 35 qtrs — |
| 51 | JACOBS LEVY EQUITY MANAGEMENT, INC | 182.3K +45.4K (+33.1%) | 12.13M +5.1M (+72.8%) | 0.27% +0.071 pp | 0.05% +0.019 pp | USD55.09 +20.8% | 2 qtrs — |
| 52 | SARISSA CAPITAL MANAGEMENT LP | 181.5K +— (+0.0%) | 12.08M +2.8M (+29.8%) | 0.27% +0.005 pp | 5.42% +0.258 pp | USD75.93 -12.4% | 6 qtrs — |
| 53 | MILLENNIUM MANAGEMENT LLC | 174.0K -269.4K (-60.8%) | 11.58M -11.2M (-49.1%) | 0.26% -0.388 pp | 0.00% -0.005 pp | USD60.55 +9.9% | 20 qtrs — |
| 54 | RETIREMENT SYSTEMS OF ALABAMA | 172.3K -2.6K (-1.5%) | 11.47M +2.5M (+27.8%) | 0.26% +0.001 pp | 0.04% +0.007 pp | USD72.68 -8.4% | 13 qtrs — |
| 55 | BRIDGEWATER ASSOCIATES, LP | 166.7K -130.2K (-43.9%) | 11.09M -4.1M (-27.1%) | 0.25% -0.185 pp | 0.04% -0.019 pp | USD85.24 -21.9% | 19 qtrs — |
| 56 | WELLS FARGO & COMPANY/MN | 165.9K +16.1K (+10.8%) | 11.04M +3.4M (+43.7%) | 0.25% +0.028 pp | 0.00% +0.001 pp | USD72.91 -8.7% | 36 qtrs — |
| 57 | CITIGROUP INC | 163.8K +143.8K (+719.9%) | 10.90M +9.9M (+963.9%) | 0.24% +0.215 pp | 0.00% +0.004 pp | USD69.14 -3.7% | 35 qtrs — |
| 58 | LOOMIS SAYLES & CO L P | 162.4K -165.2K (-50.4%) | 10.81M -6.0M (-35.7%) | 0.24% -0.237 pp | 0.01% -0.007 pp | USD50.12 +32.8% | 22 qtrs — |
| 59 | NUVEEN, LLC | 151.8K -4.0K (-2.6%) | 10.10M +2.1M (+26.4%) | 0.23% -0.002 pp | 0.00% +0.001 pp | USD97.60 -31.8% | 4 qtrs — |
| 60 | BARCLAYS PLC | 145.1K +19.1K (+15.1%) | 9.66M -4.2M (-30.2%) | 0.22% +0.032 pp | 0.00% -0.001 pp | USD86.86 -23.4% | 42 qtrs — |
| 61 | BALYASNY ASSET MANAGEMENT L.P. | 140.8K +112.2K (+391.8%) | 9.37M +7.9M (+538.2%) | 0.21% +0.168 pp | 0.01% +0.010 pp | USD64.92 +2.5% | 13 qtrs — |
| 62 | STATE OF WISCONSIN INVESTMENT BOARD | 136.4K +15.7K (+13.0%) | 9.08M +2.9M (+46.6%) | 0.20% +0.027 pp | 0.02% +0.006 pp | USD63.81 +4.3% | 17 qtrs — |
| 63 | SWISS NATIONAL BANK | 134.2K +— (+0.0%) | 8.93M +2.0M (+29.8%) | 0.20% +0.004 pp | 0.01% +0.001 pp | USD22.89 +190.7% | 35 qtrs — |
| 64 | ALLIANCEBERNSTEIN L.P. | 133.7K -5.1K (-3.6%) | 8.90M +1.8M (+25.0%) | 0.20% -0.004 pp | 0.00% +0.001 pp | USD72.70 -8.5% | 35 qtrs — |
| 65 | BRIGADE CAPITAL MANAGEMENT, LP | 127.6K -188.7K (-59.7%) | 8.49M -7.7M (-47.7%) | 0.19% -0.272 pp | 2.57% +0.575 pp | USD65.12 +2.2% | 3 qtrs — |
| 66 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 119.7K -911.0 (-0.8%) | 7.97M +1.8M (+28.8%) | 0.18% +0.002 pp | 0.00% +0.001 pp | USD68.37 -2.7% | 14 qtrs — |
| 67 | ASSETMARK, INC | 118.3K -203.0 (-0.2%) | 7.87M +1.8M (+29.5%) | 0.18% +0.003 pp | 0.02% +0.003 pp | USD81.93 -18.8% | 14 qtrs — |
| 68 | WELLINGTON MANAGEMENT GROUP LLP | 116.4K -655.6K (-84.9%) | 7.74M -31.8M (-80.4%) | 0.17% -0.954 pp | 0.00% -0.006 pp | USD89.12 -25.3% | 5 qtrs — |
| 69 | EDGESTREAM PARTNERS, L.P. | 115.3K +109.9K (+2,037.1%) | 7.67M +7.4M (+2,673.0%) | 0.17% +0.164 pp | 0.22% +0.208 pp | USD65.84 +1.1% | 2 qtrs — |
| 70 | LEGAL & GENERAL GROUP PLC | 110.5K -31.8K (-22.4%) | 7.35M +54.1K (+0.7%) | 0.16% -0.043 pp | 0.00% +0.000 pp | USD47.51 +40.1% | 35 qtrs — |
| 71 | RAYMOND JAMES FINANCIAL INC | 109.1K -4.3K (-3.8%) | 7.26M +1.4M (+24.8%) | 0.16% -0.003 pp | 0.00% +0.000 pp | USD87.94 -24.3% | 5 qtrs — |
| 72 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 100.0K +100.0K (+100.0%) | 6.66M +6.7M (+100.0%) | 0.15% +0.149 pp | 0.33% +0.330 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 73 | SECTOR GAMMA AS | 93.8K +29.4K (+45.7%) | 6.24M +2.9M (+89.0%) | 0.14% +0.046 pp | 1.42% +0.604 pp | USD72.73 -8.5% | 11 qtrs — |
| 74 | VERITION FUND MANAGEMENT LLC | 87.5K -75.5K (-46.3%) | 5.82M -2.5M (-30.3%) | 0.13% -0.108 pp | 0.02% -0.012 pp | USD57.18 +16.4% | 3 qtrs — |
| 75 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 85.8K +85.8K (+100.0%) | 5.71M +5.7M (+100.0%) | 0.13% +0.128 pp | 0.02% +0.019 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 76 | VICTORY CAPITAL MANAGEMENT INC | 84.6K -55.7K (-39.7%) | 5.63M -1.6M (-21.7%) | 0.13% -0.079 pp | 0.00% -0.001 pp | USD93.84 -29.1% | 34 qtrs — |
| 77 | INTECH INVESTMENT MANAGEMENT LLC | 81.2K +17.8K (+28.2%) | 5.41M +2.2M (+66.3%) | 0.12% +0.028 pp | 0.05% +0.019 pp | USD87.25 -23.7% | 7 qtrs — |
| 78 | AMUNDI | 78.5K +21.6K (+37.8%) | 5.22M +2.2M (+74.1%) | 0.12% +0.034 pp | 0.00% +0.001 pp | USD80.18 -17.0% | 8 qtrs — |
| 79 | COLONY GROUP, LLC | 78.4K -1.8K (-2.2%) | 5.22M +1.1M (+26.8%) | 0.12% 0.000 pp | 0.01% -0.001 pp | USD63.93 +4.1% | 9 qtrs — |
| 80 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 78.1K +13.7K (+21.4%) | 5.20M +1.9M (+57.5%) | 0.12% +0.022 pp | 0.01% +0.005 pp | USD69.78 -4.6% | 8 qtrs — |
| 81 | LPL FINANCIAL LLC | 77.0K -15.3K (-16.6%) | 5.12M +389.8K (+8.2%) | 0.11% -0.020 pp | 0.00% +0.000 pp | USD72.93 -8.7% | 21 qtrs — |
| 82 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 76.9K -24.0K (-23.8%) | 5.12M -57.5K (-1.1%) | 0.11% -0.033 pp | 0.00% +0.000 pp | USD75.30 -11.6% | 27 qtrs — |
| 83 | LSV ASSET MANAGEMENT | 76.4K +— (+0.0%) | 5.08M +1.2M (+29.7%) | 0.11% +0.002 pp | 0.01% +0.002 pp | USD74.59 -10.8% | 12 qtrs — |
| 84 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 76.2K +76.2K (+100.0%) | 5.07M +5.1M (+100.0%) | 0.11% +0.113 pp | 0.01% +0.009 pp | USD66.55 +0.0% | 1 qtrs NEW |
| 85 | RENAISSANCE TECHNOLOGIES LLC | 75.8K +16.0K (+26.7%) | 5.04M +2.0M (+64.3%) | 0.11% +0.025 pp | 0.01% +0.004 pp | USD54.50 +22.1% | 18 qtrs — |
| 86 | STANLEY-LAMAN GROUP, LTD. | 75.4K -4.2K (-5.3%) | 5.02M +933.8K (+22.8%) | 0.11% -0.004 pp | 0.64% +0.056 pp | USD58.76 +13.3% | 9 qtrs — |
| 87 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 74.7K +1.1K (+1.6%) | 4.97M +1.2M (+31.8%) | 0.11% +0.004 pp | 2.88% -0.660 pp | USD51.52 +29.2% | 2 qtrs — |
| 88 | RUSSELL INVESTMENTS GROUP, LTD. | 74.2K +6.0K (+8.8%) | 4.94M +1.4M (+41.2%) | 0.11% +0.011 pp | 0.01% +0.001 pp | USD75.34 -11.7% | 27 qtrs — |
| 89 | FRANKLIN RESOURCES INC | 74.1K +2.9K (+4.1%) | 4.93M +1.3M (+35.0%) | 0.11% +0.006 pp | 0.00% +0.000 pp | USD67.05 -0.7% | 15 qtrs — |
| 90 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 73.8K -1.5K (-2.0%) | 4.91M +1.0M (+27.1%) | 0.11% 0.000 pp | 0.01% +0.002 pp | USD23.68 +181.0% | 35 qtrs — |
| 91 | ASSENAGON ASSET MANAGEMENT S.A. | 71.9K -1.2M (-94.4%) | 4.79M -60.9M (-92.7%) | 0.11% -1.761 pp | 0.01% -0.083 pp | USD51.29 +29.8% | 6 qtrs — |
| 92 | METLIFE INVESTMENT MANAGEMENT, LLC | 68.2K -5.6K (-7.5%) | 4.54M +756.0K (+20.0%) | 0.10% -0.006 pp | 0.02% +0.004 pp | USD45.21 +47.2% | 33 qtrs — |
| 93 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 66.3K -4.2K (-6.0%) | 4.41M +794.4K (+22.0%) | 0.10% -0.004 pp | 0.00% +0.001 pp | USD65.37 +1.8% | 40 qtrs — |
| 94 | CREATIVE PLANNING | 64.0K +36.3K (+131.0%) | 4.26M +2.8M (+199.7%) | 0.10% +0.055 pp | 0.00% +0.002 pp | USD64.96 +2.4% | 28 qtrs — |
| 95 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 64.0K -89.0 (-0.1%) | 4.26M +971.6K (+29.6%) | 0.10% +0.002 pp | 0.00% +0.001 pp | USD17.28 +285.1% | 35 qtrs — |
| 96 | SKYOAK WEALTH, LLC | 63.1K +4.9K (+8.4%) | 4.20M +1.2M (+40.6%) | 0.09% +0.009 pp | 0.76% +0.191 pp | USD64.86 +2.6% | 16 qtrs — |
| 97 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 61.7K +3.4K (+5.9%) | 4.11M +1.1M (+37.6%) | 0.09% +0.007 pp | 0.01% +0.002 pp | USD88.18 -24.5% | 5 qtrs — |
| 98 | STIFEL FINANCIAL CORP | 60.0K +2.9K (+5.1%) | 3.99M +1.1M (+36.3%) | 0.09% +0.006 pp | 0.00% +0.001 pp | USD61.72 +7.8% | 20 qtrs — |
| 99 | LIDO ADVISORS, LLC | 62.2K -5.0K (-7.4%) | 3.35M -98.5K (-2.9%) | 0.09% -0.006 pp | 0.01% -0.001 pp | USD83.62 -20.4% | 5 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
0.76
Neutral
Buys
4
Sells
4
Shares acquired
48.5K
Shares disposed
64.2K
Cash buys
—
Cash sales
—
Net activity
-15,616
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 1,911 | 83.82 | 160.2K | 117,465 | D | ↗ |
| 2026-03-05 | Niedzwiecki Daniel | Officer | A-Award | A | Common Stock | 36,692 | 0.00 | — | 120,659 | D | ↗ |
| 2026-03-05 | Morgan Amanda Michelle | Officer | A-Award | A | Common Stock | 26,208 | 0.00 | — | 64,748 | D | ↗ |
| 2026-03-05 | Marshall Robert J. Jr. | Officer | A-Award | A | Common Stock | 38,002 | 0.00 | — | 123,974 | D | ↗ |
| 2026-03-05 | Dinkelborg Ludger | Officer | A-Award | A | Common Stock | 20,966 | 0.00 | — | 35,731 | D | ↗ |
| 2026-03-05 | Brown Kimberly | Officer | A-Award | A | Common Stock | 6,158 | 0.00 | — | 13,859 | D | ↗ |
| 2026-03-02 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 8,259 | 76.30 | 630.2K | 83,967 | D | ↗ |
| 2026-03-02 | Morgan Amanda Michelle | Officer | F-InKind | D | Common Stock | 3,336 | 76.30 | 254.5K | 38,540 | D | ↗ |
| 2026-03-02 | Marshall Robert J. Jr. | Officer | A-Award | A | Common Stock | 8,491 | 0.00 | — | 96,624 | D | ↗ |
| 2026-03-02 | Heino Mary Anne | Director / Officer | F-InKind | D | Common Stock | 41,916 | 76.30 | 3.20M | 323,124 | D | ↗ |
| 2025-12-15 | Morgan Amanda Michelle | Officer | F-InKind | D | Common Stock | 368 | 66.57 | 24.5K | 39,094 | D | ↗ |
| 2025-11-17 | Heino Mary Anne | Director / Officer | A-Award | A | Common Stock | 14,285 | 0.00 | — | 332,935 | D | ↗ |
| 2025-08-29 | Marshall Robert J. Jr. | Officer | F-InKind | D | Common Stock | 727 | 54.90 | 39.9K | 88,133 | D | ↗ |
| 2025-08-20 | PATEL RAJIV A | 10% Owner | S-Sale | D | Common Stock | 3,365,000 | 56.15 | 188.94M | 3,477,227 | I | ↗ |
| 2025-08-20 | FARALLON PARTNERS L L C/CA | 10% Owner | S-Sale | D | Common Stock | 3,365,000 | 56.15 | 188.94M | 3,477,227 | I | ↗ |
| 2025-08-19 | PATEL RAJIV A | 10% Owner | S-Sale | D | Common Stock | 41,000 | 55.34 | 2.27M | 6,842,227 | I | ↗ |
| 2025-08-19 | FARALLON PARTNERS L L C/CA | 10% Owner | S-Sale | D | Common Stock | 41,000 | 55.34 | 2.27M | 6,842,227 | I | ↗ |
| 2025-08-15 | Dinkelborg Ludger | Officer | A-Award | A | Stock Option (right to buy) | 25,324 | 54.18 | 1.37M | 25,324 | D | ↗ |
| 2025-08-15 | Brown Kimberly | Officer | F-InKind | D | Common Stock | 463 | 54.18 | 25.1K | 7,701 | D | ↗ |
| 2025-08-13 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 3,060 | 53.57 | 163.9K | 108,214 | D | ↗ |
| 2025-08-06 | PATEL RAJIV A | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 6,883,227 | I | ↗ |
| 2025-08-06 | FARALLON PARTNERS L L C/CA | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 6,883,227 | I | ↗ |
| 2025-08-01 | Dinkelborg Ludger | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-07-15 | Blanchfield Paul | Officer | F-InKind | D | Common Stock | 518 | 81.26 | 42.1K | 111,274 | D | ↗ |
| 2025-06-13 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 6,000 | 78.74 | 472.4K | 87,057 | D | ↗ |
| 2025-06-09 | McHugh Julie | Director | S-Sale | D | Common Stock | 5,192 | 81.62 | 423.8K | 25,962 | D | ↗ |
| 2025-06-09 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 27,036 | 83.40 | 2.25M | 88,860 | D | ↗ |
| 2025-06-05 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 6,000 | 79.65 | 477.9K | 93,057 | D | ↗ |
| 2025-06-05 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 6,599 | 79.65 | 525.6K | 111,792 | D | ↗ |
| 2025-06-02 | Heino Mary Anne | Director | S-Sale | D | Common Stock | 3,140 | 74.90 | 235.2K | 341,576 | D | ↗ |
| 2025-05-27 | Heino Mary Anne | Director | G-Gift | A | Common Stock | 179,300 | 0.00 | — | 179,300 | I | ↗ |
| 2025-05-15 | Pruden Gary J | Director | G-Gift | D | Common Stock | 2,635 | 0.00 | — | 2,537 | D | ↗ |
| 2025-05-14 | Thrall James H | Director | A-Award | A | Stock Option (right to buy) | 4,543 | 78.81 | 358.0K | 4,543 | D | ↗ |
| 2025-05-14 | Pruden Gary J | Director | A-Award | A | Stock Option (right to buy) | 4,543 | 78.81 | 358.0K | 4,543 | D | ↗ |
| 2025-05-14 | Morrow Phuong Khanh | Director | A-Award | A | Common Stock | 2,537 | 0.00 | — | 3,100 | D | ↗ |
| 2025-05-14 | McHugh Julie | Director | A-Award | A | Stock Option (right to buy) | 4,543 | 78.81 | 358.0K | 4,543 | D | ↗ |
| 2025-05-14 | Maeusli Heinz Christoph | Director | A-Award | A | Stock Option (right to buy) | 4,543 | 78.81 | 358.0K | 4,543 | D | ↗ |
| 2025-05-14 | LENO SAM R | Director | A-Award | A | Stock Option (right to buy) | 4,543 | 78.81 | 358.0K | 4,543 | D | ↗ |
| 2025-05-14 | Heino Mary Anne | Director | A-Award | A | Common Stock | 2,537 | 0.00 | — | 394,716 | D | ↗ |
| 2025-05-14 | EASTLAND JULIA MARIE | Director | A-Award | A | Stock Option (right to buy) | 4,543 | 78.81 | 358.0K | 4,543 | D | ↗ |
| 2025-05-14 | Ber Gerard | Director | A-Award | A | Stock Option (right to buy) | 4,543 | 78.81 | 358.0K | 4,543 | D | ↗ |
| 2025-05-14 | Baylor-Henry Minnie | Director | A-Award | A | Common Stock | 2,537 | 0.00 | — | 9,881 | D | ↗ |
| 2025-05-09 | Ber Gerard | Director | F-InKind | D | Common Stock | 396 | 81.74 | 32.4K | 20,825 | D | ↗ |
| 2025-04-17 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 178 | 101.32 | 18.0K | 99,057 | D | ↗ |
| 2025-04-17 | Blanchfield Paul | Officer | F-InKind | D | Common Stock | 455 | 101.32 | 46.1K | 118,391 | D | ↗ |
| 2025-03-17 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 10,000 | 100.52 | 1.01M | 113,860 | D | ↗ |
| 2025-03-13 | Heino Mary Anne | Director | G-Gift | A | Common Stock | 8,618 | 0.00 | — | 8,618 | I | ↗ |
| 2025-03-05 | Niedzwiecki Daniel | Officer | A-Award | A | Stock Option (right to buy) | 13,927 | 100.48 | 1.40M | 13,927 | D | ↗ |
| 2025-03-05 | Morgan Amanda Michelle | Officer | A-Award | A | Common Stock | 14,928 | 0.00 | — | 39,580 | D | ↗ |
| 2025-03-05 | Marshall Robert J. Jr. | Officer | A-Award | A | Stock Option (right to buy) | 13,927 | 100.48 | 1.40M | 13,927 | D | ↗ |
| 2025-03-05 | MARKISON BRIAN A | Director / Officer | A-Award | A | Stock Option (right to buy) | 41,347 | 100.48 | 4.15M | 41,347 | D | ↗ |
| 2025-03-05 | Brown Kimberly | Officer | A-Award | A | Stock Option (right to buy) | 2,002 | 100.48 | 201.2K | 2,002 | D | ↗ |
| 2025-03-05 | Blanchfield Paul | Officer | A-Award | A | Stock Option (right to buy) | 15,668 | 100.48 | 1.57M | 15,668 | D | ↗ |
| 2025-03-03 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 12,907 | 94.86 | 1.22M | 75,351 | D | ↗ |
| 2025-03-03 | Morgan Amanda Michelle | Officer | F-InKind | D | Common Stock | 759 | 94.86 | 72.0K | 24,652 | D | ↗ |
| 2025-03-03 | Marshall Robert J. Jr. | Officer | A-Award | A | Common Stock | 17,274 | 0.00 | — | 120,237 | D | ↗ |
| 2025-03-03 | MARKISON BRIAN A | Director / Officer | F-InKind | D | Common Stock | 8,637 | 94.86 | 819.3K | 161,511 | D | ↗ |
| 2025-03-03 | Heino Mary Anne | Director | S-Sale | D | Common Stock | 4,971 | 95.91 | 476.8K | 440,399 | D | ↗ |
| 2025-03-03 | Blanchfield Paul | Officer | A-Award | A | Common Stock | 13,769 | 0.00 | — | 110,506 | D | ↗ |
| 2025-02-07 | Morrow Phuong Khanh | Director | A-Award | A | Stock Option (right to buy) | 1,015 | 88.71 | 90.0K | 1,015 | D | ↗ |
| 2025-02-01 | Morrow Phuong Khanh | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-01-15 | Thrall James H | Director | S-Sale | D | Common Stock | 1,000 | 94.76 | 94.8K | 33,207 | D | ↗ |
| 2024-12-19 | MARKISON BRIAN A | Director / Officer | M-Exempt | A | Common Stock | 16,666 | 6.00 | 100.0K | 185,594 | D | ↗ |
| 2024-12-15 | Morgan Amanda Michelle | Officer | F-InKind | D | Common Stock | 356 | 93.48 | 33.3K | 25,055 | D | ↗ |
| 2024-11-15 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 10,000 | 81.20 | 812.0K | 102,963 | D | ↗ |
| 2024-11-14 | Blanchfield Paul | Officer | G-Gift | D | Common Stock | 355 | 0.00 | — | 96,737 | D | ↗ |
| 2024-11-08 | Heino Mary Anne | Director | S-Sale | D | Common Stock | 7,487 | 86.32 | 646.3K | 447,436 | D | ↗ |
| 2024-09-10 | EASTLAND JULIA MARIE | Director | A-Award | A | Stock Option (right to buy) | 2,506 | 99.08 | 248.3K | 2,506 | — | ↗ |
| 2024-09-03 | EASTLAND JULIA MARIE | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-29 | Marshall Robert J. Jr. | Officer | F-InKind | D | Common Stock | 786 | 104.81 | 82.4K | 112,963 | — | ↗ |
| 2024-08-21 | Thrall James H | Director | S-Sale | D | Common Stock | 1,000 | 98.52 | 98.5K | 34,207 | — | ↗ |
| 2024-08-15 | Brown Kimberly | Officer | A-Award | A | Common Stock | 4,731 | 0.00 | — | 4,731 | — | ↗ |
| 2024-08-14 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 2,500 | 97.54 | 243.9K | 77,744 | — | ↗ |
| 2024-08-12 | Ber Gerard | Director | S-Sale | D | Common Stock | 11,175 | 96.23 | 1.08M | 25,546 | — | ↗ |
| 2024-08-08 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 2,000 | 96.39 | 192.8K | 98,980 | — | ↗ |
| 2024-08-02 | Heino Mary Anne | Director | S-Sale | D | Common Stock | 96 | 96.68 | 9.3K | 454,923 | — | ↗ |
| 2024-08-01 | Brown Kimberly | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-16 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 1,796 | 124.96 | 224.4K | 60,420 | — | ↗ |
| 2024-07-15 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 123.15 | 42.0K | 62,216 | — | ↗ |
| 2024-07-15 | Blanchfield Paul | Officer | F-InKind | D | Common Stock | 518 | 123.19 | 63.8K | 100,980 | — | ↗ |
| 2024-07-10 | Pruden Gary J | Director | S-Sale | D | Common Stock | 12,530 | 95.04 | 1.19M | 11,978 | — | ↗ |
| 2024-06-17 | Humphrey Jeffrey | Officer | A-Award | A | Stock Option (right to buy) | 16,188 | 82.63 | 1.34M | 16,188 | — | ↗ |
| 2024-06-13 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 79.77 | 27.2K | 62,557 | — | ↗ |
| 2024-06-07 | Heino Mary Anne | Director | S-Sale | D | Common Stock | 1 | 81.26 | 81.26 | 37,719 | I | ↗ |
| 2024-05-31 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 1,179 | 80.82 | 95.3K | 101,498 | — | ↗ |
| 2024-05-30 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 12,873 | 79.86 | 1.03M | 80,244 | — | ↗ |
| 2024-05-28 | McHugh Julie | Director | S-Sale | D | Common Stock | 2,500 | 78.50 | 196.3K | 28,617 | — | ↗ |
| 2024-05-28 | Maeusli Heinz Christoph | Director | S-Sale | D | Common Stock | 5,959 | 79.67 | 474.8K | 23,440 | — | ↗ |
| 2024-05-28 | Humphrey Jeffrey | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | Pruden Gary J | Director | G-Gift | D | Common Stock | 2,012 | 0.00 | — | 2,635 | — | ↗ |
| 2024-05-17 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 1,466 | 79.67 | 116.8K | 93,117 | — | ↗ |
| 2024-05-13 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 76.89 | 26.2K | 62,898 | — | ↗ |
| 2024-05-13 | Ber Gerard | Director | F-InKind | D | Common Stock | 302 | 77.88 | 23.5K | 36,721 | — | ↗ |
| 2024-05-09 | Thrall James H | Director | A-Award | A | Stock Option (right to buy) | 4,853 | 75.90 | 368.3K | 4,853 | — | ↗ |
| 2024-05-09 | Pruden Gary J | Director | A-Award | A | Stock Option (right to buy) | 4,853 | 75.90 | 368.3K | 4,853 | — | ↗ |
| 2024-05-09 | McHugh Julie | Director | A-Award | A | Common Stock | 2,635 | 0.00 | — | 31,117 | — | ↗ |
| 2024-05-09 | Maeusli Heinz Christoph | Director | A-Award | A | Stock Option (right to buy) | 4,853 | 75.90 | 368.3K | 4,853 | — | ↗ |
| 2024-05-09 | LENO SAM R | Director | A-Award | A | Common Stock | 2,635 | 0.00 | — | 60,572 | — | ↗ |
| 2024-05-09 | Heino Mary Anne | Director | A-Award | A | Common Stock | 2,635 | 0.00 | — | 424,144 | — | ↗ |
| 2024-05-09 | Ber Gerard | Director | A-Award | A | Common Stock | 2,635 | 0.00 | — | 37,350 | — | ↗ |
| 2024-05-09 | Baylor-Henry Minnie | Director | A-Award | A | Stock Option (right to buy) | 4,853 | 75.90 | 368.3K | 4,853 | — | ↗ |
| 2024-04-17 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 177 | 61.48 | 10.9K | 94,583 | — | ↗ |
| 2024-04-17 | Blanchfield Paul | Officer | F-InKind | D | Common Stock | 455 | 61.48 | 28.0K | 102,677 | — | ↗ |
| 2024-04-15 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 61.24 | 20.9K | 63,239 | — | ↗ |
| 2024-03-25 | Morgan Amanda Michelle | Officer | — | D | Common Stock | 0 | 0.00 | — | 25,411 | — | ↗ |
| 2024-03-15 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 20,000 | 60.00 | 1.20M | 113,749 | — | ↗ |
| 2024-03-13 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 60.48 | 20.6K | 63,204 | — | ↗ |
| 2024-03-07 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 18,023 | 61.96 | 1.12M | 103,357 | — | ↗ |
| 2024-03-06 | LENO SAM R | Director | M-Exempt | D | Stock Option (right to buy) | 2,045 | 16.30 | 33.3K | 0 | — | ↗ |
| 2024-03-05 | Sabens Andrea | Officer | F-InKind | D | Common Stock | 6,360 | 65.36 | 415.7K | 63,545 | — | ↗ |
| 2024-03-05 | Provost Jean-Claude | Officer | F-InKind | D | Common Stock | 546 | 65.36 | 35.7K | 38,841 | — | ↗ |
| 2024-03-05 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 8,457 | 65.36 | 552.7K | 94,760 | — | ↗ |
| 2024-03-05 | Montagut Etienne | Officer | F-InKind | D | Common Stock | 25,574 | 65.36 | 1.67M | 94,651 | — | ↗ |
| 2024-03-05 | Marshall Robert J. Jr. | Officer | F-InKind | D | Common Stock | 35,730 | 65.36 | 2.34M | 133,749 | — | ↗ |
| 2024-03-05 | LENO SAM R | Director | S-Sale | D | Common Stock | 316 | 65.44 | 20.7K | 57,937 | — | ↗ |
| 2024-03-05 | Blanchfield Paul | Officer | F-InKind | D | Common Stock | 20,728 | 65.36 | 1.35M | 121,380 | — | ↗ |
| 2024-03-04 | Sabens Andrea | Officer | A-Award | A | Common Stock | 5,817 | 0.00 | — | 69,905 | — | ↗ |
| 2024-03-04 | Niedzwiecki Daniel | Officer | A-Award | A | Common Stock | 6,466 | 0.00 | — | 103,217 | — | ↗ |
| 2024-03-04 | Montagut Etienne | Officer | A-Award | A | Common Stock | 21,645 | 0.00 | — | 120,225 | — | ↗ |
| 2024-03-04 | Marshall Robert J. Jr. | Officer | A-Award | A | Common Stock | 29,762 | 0.00 | — | 169,479 | — | ↗ |
| 2024-03-04 | LENO SAM R | Director | M-Exempt | D | Stock Option (right to buy) | 7,943 | 12.59 | 100.0K | 0 | — | ↗ |
| 2024-03-04 | Heino Mary Anne | Director | S-Sale | D | Common Stock | 100 | 66.23 | 6.6K | 251,643 | — | ↗ |
| 2024-03-04 | Blanchfield Paul | Officer | A-Award | A | Common Stock | 16,910 | 0.00 | — | 142,108 | — | ↗ |
| 2024-03-01 | Sabens Andrea | Officer | A-Award | A | Stock Option (right to buy) | 3,368 | 64.64 | 217.7K | 3,368 | — | ↗ |
| 2024-03-01 | Provost Jean-Claude | Officer | A-Award | A | Common Stock | 18,564 | 0.00 | — | 39,387 | — | ↗ |
| 2024-03-01 | Niedzwiecki Daniel | Officer | A-Award | A | Common Stock | 30,456 | 0.00 | — | 96,751 | — | ↗ |
| 2024-03-01 | Montagut Etienne | Officer | A-Award | A | Common Stock | 31,326 | 0.00 | — | 98,580 | — | ↗ |
| 2024-03-01 | Marshall Robert J. Jr. | Officer | A-Award | A | Stock Option (right to buy) | 21,652 | 64.64 | 1.40M | 21,652 | — | ↗ |
| 2024-03-01 | MARKISON BRIAN A | Director / Officer | A-Award | A | Common Stock | 131,496 | 0.00 | — | 152,826 | — | ↗ |
| 2024-03-01 | Blanchfield Paul | Officer | A-Award | A | Common Stock | 36,547 | 0.00 | — | 125,198 | — | ↗ |
| 2024-02-13 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 55.31 | 18.9K | 58,403 | — | ↗ |
| 2024-01-16 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 56.01 | 19.1K | 58,744 | — | ↗ |
| 2023-12-15 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 10,000 | 78.24 | 782.4K | 103,170 | — | ↗ |
| 2023-12-13 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 75.62 | 25.8K | 59,085 | — | ↗ |
| 2023-12-13 | Heino Mary Anne | Director / Officer | G-Gift | D | Common Stock | 53,350 | 0.00 | — | 264,337 | — | ↗ |
| 2023-11-16 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 1,500 | 67.96 | 101.9K | 88,651 | — | ↗ |
| 2023-11-13 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 341 | 63.57 | 21.7K | 59,426 | — | ↗ |
| 2023-11-13 | Heino Mary Anne | Director / Officer | S-Sale | D | Common Stock | 5,912 | 63.32 | 374.3K | 323,555 | — | ↗ |
| 2023-09-15 | Niedzwiecki Daniel | Officer | M-Exempt | A | Common Stock | 2,846 | 17.79 | 50.6K | 69,141 | — | ↗ |
| 2023-08-29 | Marshall Robert J. Jr. | Officer | A-Award | A | Common Stock | 4,872 | 0.00 | — | 113,170 | — | ↗ |
| 2023-08-21 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 408 | 66.10 | 27.0K | 90,067 | — | ↗ |
| 2023-08-18 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 1,500 | 65.19 | 97.8K | 90,475 | — | ↗ |
| 2023-08-15 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 10,000 | 68.52 | 685.2K | 108,298 | — | ↗ |
| 2023-08-11 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 4,297 | 67.93 | 291.9K | 66,295 | — | ↗ |
| 2023-08-11 | Heino Mary Anne | Director / Officer | S-Sale | D | Common Stock | 4,428 | 68.22 | 302.1K | 335,989 | — | ↗ |
| 2023-07-19 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 1,752 | 90.87 | 159.2K | 59,767 | — | ↗ |
| 2023-07-18 | Blanchfield Paul | Officer | F-InKind | D | Common Stock | 518 | 87.40 | 45.3K | 91,975 | — | ↗ |
| 2023-06-02 | Baylor-Henry Minnie | Director | S-Sale | D | Common Stock | 6 | 86.22 | 517.35 | 16 | — | ↗ |
| 2023-05-18 | Niedzwiecki Daniel | Officer | F-InKind | D | Common Stock | 1,466 | 97.97 | 143.6K | 70,592 | — | ↗ |
| 2023-05-18 | Blanchfield Paul | Officer | G-Gift | D | Common Stock | 250 | 0.00 | — | 92,493 | — | ↗ |
| 2023-05-15 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 385 | 99.36 | 38.3K | 61,519 | — | ↗ |
| 2023-05-15 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 10,000 | 99.36 | 993.6K | 118,298 | — | ↗ |
| 2023-05-11 | Thrall James H | Director | A-Award | A | Common Stock | 2,012 | 0.00 | — | 32,572 | — | ↗ |
| 2023-05-11 | Pruden Gary J | Director | A-Award | A | Common Stock | 2,012 | 0.00 | — | 32,957 | — | ↗ |
| 2023-05-11 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 6,113 | 98.82 | 604.1K | 72,058 | — | ↗ |
| 2023-05-11 | McHugh Julie | Director | A-Award | A | Common Stock | 2,012 | 0.00 | — | 28,482 | — | ↗ |
| 2023-05-11 | Maeusli Heinz Christoph | Director | A-Award | A | Stock Option (right to buy) | 3,798 | 99.38 | 377.4K | 3,798 | — | ↗ |
| 2023-05-11 | MARKISON BRIAN A | Director | A-Award | A | Stock Option (right to buy) | 3,798 | 99.38 | 377.4K | 3,798 | — | ↗ |
| 2023-05-11 | LENO SAM R | Director | A-Award | A | Stock Option (right to buy) | 3,798 | 99.38 | 377.4K | 3,798 | — | ↗ |
| 2023-05-11 | Ber Gerard | Director | A-Award | A | Stock Option (right to buy) | 3,798 | 99.38 | 377.4K | 3,798 | — | ↗ |
| 2023-05-11 | Baylor-Henry Minnie | Director | A-Award | A | Common Stock | 2,012 | 0.00 | — | 4,709 | — | ↗ |
| 2023-05-08 | Ber Gerard | Director | F-InKind | D | Common Stock | 327 | 94.82 | 31.0K | 37,023 | — | ↗ |
| 2023-04-17 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 386 | 88.67 | 34.2K | 61,904 | — | ↗ |
| 2023-04-17 | Niedzwiecki Daniel | Officer | A-Award | A | Common Stock | 3,301 | 0.00 | — | 78,171 | — | ↗ |
| 2023-04-17 | Montagut Etienne | Officer | S-Sale | D | Common Stock | 2,118 | 88.67 | 187.8K | 67,254 | — | ↗ |
| 2023-04-17 | Blanchfield Paul | Officer | A-Award | A | Common Stock | 8,464 | 0.00 | — | 95,028 | — | ↗ |
| 2023-04-03 | Montagut Etienne | — | S-Sale | D | Common Stock | 3,684 | 82.09 | 302.4K | 69,372 | — | ↗ |
| 2023-03-27 | Montagut Etienne | — | S-Sale | D | Common Stock | 14,528 | 81.13 | 1.18M | 73,056 | — | ↗ |
| 2023-03-27 | MARKISON BRIAN A | — | S-Sale | D | Common Stock | 13,290 | 81.13 | 1.08M | 19,318 | — | ↗ |
| 2023-03-27 | LENO SAM R | Director | S-Sale | D | Common Stock | 4,675 | 80.46 | 376.2K | 58,262 | — | ↗ |
| 2023-03-27 | Heino Mary Anne | Director / Officer | S-Sale | D | Common Stock | 15,822 | 81.30 | 1.29M | 419,397 | — | ↗ |
| 2023-03-15 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 386 | 71.58 | 27.6K | 62,290 | — | ↗ |
| 2023-03-15 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 5,000 | 71.58 | 357.9K | 128,298 | — | ↗ |
| 2023-03-08 | Heino Mary Anne | Director / Officer | S-Sale | D | Common Stock | 5,320 | 74.18 | 394.6K | 724,141 | — | ↗ |
| 2023-03-07 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 950 | 72.15 | 68.5K | 62,676 | — | ↗ |
| 2023-03-07 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 1,055 | 72.15 | 76.1K | 74,870 | — | ↗ |
| 2023-03-07 | Montagut Etienne | Officer | S-Sale | D | Common Stock | 3,531 | 72.15 | 254.8K | 87,294 | — | ↗ |
| 2023-03-07 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 4,854 | 72.15 | 350.2K | 133,298 | — | ↗ |
| 2023-03-07 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 2,758 | 72.15 | 199.0K | 86,343 | — | ↗ |
| 2023-03-06 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 7,705 | 72.56 | 559.1K | 63,626 | — | ↗ |
| 2023-03-06 | Niedzwiecki Daniel | Officer | S-Sale | D | Common Stock | 9,079 | 72.56 | 658.8K | 75,925 | — | ↗ |
| 2023-03-06 | Montagut Etienne | Officer | S-Sale | D | Common Stock | 14,179 | 72.56 | 1.03M | 90,825 | — | ↗ |
| 2023-03-06 | Marshall Robert J. Jr. | Officer | S-Sale | D | Common Stock | 20,587 | 72.56 | 1.49M | 138,152 | — | ↗ |
| 2023-03-06 | Heino Mary Anne | Director / Officer | S-Sale | D | Common Stock | 12,189 | 73.24 | 892.8K | 729,461 | — | ↗ |
| 2023-03-06 | Blanchfield Paul | Officer | S-Sale | D | Common Stock | 5,250 | 72.56 | 380.9K | 89,101 | — | ↗ |
| 2023-03-03 | Sabens Andrea | Officer | A-Award | A | Common Stock | 7,099 | 0.00 | — | 71,331 | — | ↗ |
| 2023-03-03 | Niedzwiecki Daniel | Officer | A-Award | A | Common Stock | 7,515 | 0.00 | — | 85,004 | — | ↗ |
| 2023-03-03 | Montagut Etienne | Officer | A-Award | A | Common Stock | 12,361 | 0.00 | — | 105,004 | — | ↗ |
| 2023-03-03 | Marshall Robert J. Jr. | Officer | A-Award | A | Common Stock | 17,391 | 0.00 | — | 158,739 | — | ↗ |
| 2023-03-03 | Heino Mary Anne | Director / Officer | A-Award | A | Common Stock | 74,486 | 0.00 | — | 823,705 | — | ↗ |
| 2023-03-02 | Sabens Andrea | Officer | A-Award | A | Stock Option (right to buy) | 1,936 | 73.35 | 142.0K | 1,936 | — | ↗ |
| 2023-03-02 | Provost Jean-Claude | Officer | A-Award | A | Common Stock | 16,359 | 0.00 | — | 20,823 | — | ↗ |
| 2023-03-02 | Niedzwiecki Daniel | Officer | A-Award | A | Stock Option (right to buy) | 7,196 | 73.35 | 527.8K | 7,196 | — | ↗ |
| 2023-03-02 | Montagut Etienne | Officer | A-Award | A | Stock Option (right to buy) | 8,141 | 73.35 | 597.1K | 8,141 | — | ↗ |
| 2023-03-02 | Marshall Robert J. Jr. | Officer | A-Award | A | Stock Option (right to buy) | 11,822 | 73.35 | 867.1K | 11,822 | — | ↗ |
| 2023-03-02 | Heino Mary Anne | Director / Officer | A-Award | A | Common Stock | 76,686 | 0.00 | — | 749,219 | — | ↗ |
| 2023-03-02 | Blanchfield Paul | Officer | A-Award | A | Stock Option (right to buy) | 11,880 | 73.35 | 871.4K | 11,880 | — | ↗ |
| 2023-02-15 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 386 | 57.52 | 22.2K | 60,460 | — | ↗ |
| 2023-01-17 | Sabens Andrea | Officer | S-Sale | D | Common Stock | 386 | 52.97 | 20.4K | 60,846 | — | ↗ |
| 2023-01-01 | Provost Jean-Claude | Officer | — | I | Common Stock | 0 | 0.00 | — | 4,464 | — | ↗ |
Executive team
Top executives
EBIT / Employee
412.8K
Shares Outstanding
65.10M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2017 | Mary Anne Heino President and Chief Executive Officer | 629.2K | — | 1.89M | — | 1.17M | 13.5K | 3.71M | 51.01% | ↗ |
| 2 | 2017 | Michael Duffy Senior Vice President, Strategy and Business Development, General Counsel and Secretary | 391.4K | — | 472.1K | — | 333.9K | 13.5K | 1.21M | 38.99% | ↗ |
| 3 | 2017 | Timothy Healey Senior Vice President, Commercial | 388.3K | — | 471.0K | — | 321.5K | 13.5K | 1.19M | 39.44% | ↗ |
| 4 | 2017 | John W. Crowley Chief Financial Officer | 366.6K | — | 428.2K | — | 338.9K | 13.5K | 1.15M | 37.33% | ↗ |
| 5 | 2016 | Mary Anne Heino President and Chief Executive Officer | 600.0K | — | 519.4K | — | 850.0K | 13.2K | 1.98M | 26.20% | ↗ |
| 6 | 2016 | John W. Crowley Chief Financial Officer | 340.3K | 50.0K | 206.0K | — | 234.5K | 13.2K | 844.1K | 24.41% | ↗ |
| 7 | 2016 | Michael Duffy Senior Vice President, Strategy and Business Development, General Counsel and Secretary | 380.0K | — | 121.5K | — | 261.0K | 13.2K | 775.8K | 15.66% | ↗ |
| 8 | 2015 | Mary Anne Heino President and Chief Executive Officer | 470.8K | — | 1.69M | 6.7K | 591.4K | 13.3K | 2.77M | 61.19% | ↗ |
| 9 | 2015 | Jeffrey Bailey Former President and Chief Executive Officer | 422.5K | — | 1.44M | 14.5K | — | 603.1K | 2.48M | 58.59% | ↗ |
| 10 | 2015 | Michael Duffy Senior Vice President, Strategy and Business Development, General Counsel and Secretary | 360.9K | — | 520.1K | 35.8K | 185.0K | 13.1K | 1.11M | 49.87% | ↗ |
| 11 | 2015 | Cesare Orlandi Chief Medical Officer | 398.7K | — | 329.2K | 3.1K | 154.0K | 13.3K | 898.3K | 36.99% | ↗ |
| 12 | 2015 | John W. Crowley Chief Financial Officer | 284.7K | — | 306.9K | — | 121.0K | 13.1K | 725.7K | 42.30% | ↗ |
| 13 | 2014 | Jeffrey Bailey Former President and Chief Executive Officer | 484.6K | — | — | — | 635.0K | 39.3K | 1.16M | 0.00% | ↗ |
| 14 | 2014 | Mary Anne Heino President and Chief Executive Officer | 353.8K | — | — | — | 210.0K | 45.1K | 608.9K | 0.00% | ↗ |
| 15 | 2014 | Cesare Orlandi Chief Medical Officer | 372.6K | — | — | — | 179.0K | 13.0K | 564.6K | 0.00% | ↗ |
| 16 | 2014 | Michael Duffy Senior Vice President, Strategy and Business Development, General Counsel and Secretary | 328.2K | — | — | — | 167.0K | 9.2K | 504.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ludger Dinkelborg | Head of Research & Development | 14M | — |
| Brian A. Markison | Strategic Advisor | 1M | male |
| Robert J. Marshall Jr. | Chief Financial Officer & Treasurer | 991.7K | male |
| Thomas Reiner | Chief Science Officer | 894.8K | male |
| Jean-Claude Provost | Chief Science Officer | 894.8K | — |
| Daniel Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary | 763.1K | male |
| Amanda Morgan | Chief Commercial Officer | 677.4K | female |
| Mary Anne Heino | Interim CEO & Executive Chairperson | 674.0K | female |
| Lee Anne Howe | Chief Information Officer | — | female |
| Mark Richard Kinarney | Vice President of Investor Relations | — | male |
| Neil Holland | Vice President of Business Insights & Operations | — | male |
| Kimberly Brown | Chief Accounting Officer | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LNTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
